A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder

British Journal of Rheumatology

Volumn 37, Issue 12, 1998, Pages 1279-1286

  Hannonen, P ^c   Malminiemi, K ^a   Yli Kerttula, U ^a   Isomeri, R ^b   Roponen, P ^b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^c Central Hospital   (Finland)

Author keywords

Amitriptyline; Drug trial; Fibromyalgia; Moclobemide

Indexed keywords

AMITRIPTYLINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; FIBROMYALGIA; HEADACHE; HEALTH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP; SOMNOLENCE; SYNCOPE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AMITRIPTYLINE; ANALGESICS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZAMIDES; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; MENTAL DISORDERS; MIDDLE AGED; MOCLOBEMIDE; PATIENT COMPLIANCE; PLACEBOS; QUALITY OF LIFE;

EID: 0032445842     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Quimby LG, Block SR, Gratwick GM. Fibromyalgia: generalized pain intolerance and manifold symptom reporting. J Rheumatol 1988;15:1264-70.
2. Doherty M, Jones A. ABC of rheumatology. Fibromyalgia syndrome. Br Med J 1995;310:386-9.
3. Wolfe F, Smythe HA, Yunus MB et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72.
4. Croft P, Schollum J, Sillman A. Population study of tender point counts and pain as evidence of fibromyalgia. Br Med J 1994;309:696-9.
5. Croft P, Burt J, Schollum J, Thomas E, Macfarlane G, Sillman A. More pain, more tender points: is fibromyalgia just one end of a continuous spectrum? Ann Rheum Dis 1996;55:482-5.
6. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
7. Forseth KO, Gran JT. The prevalence of fibromyalgia among women aged 20-49 years in Arendal, Norway. Scand J Rheumatol 1992;21:74-8.
8. Ledingham J, Doherty S, Doherty M. Primary fibromyalgia syndrome - an outcome study. Br J Rheumatol 1993;32:139-42.
9. Kennedy M, Felson DT. A prospective long-term study of fibromyalgia syndrome. Arthritis Rheum 1996;39: 682-5.
10. Simms RW. Is there muscle pathology in fibromyalgia syndrome? In Goldenberg DL, ed. Rheum Dis Clin North Am 1996;22:245-66.
11. Mountz JM, Bradley LA, Modell JG et al. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum 1995;38:926-38.
12. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with the fibromyalgia syndrome. A possible link between sleep and muscle pain. Arthritis Rheum 1992;35:1113-6.
13. Ferraccioli G, Guerra P, Rizzi V, Baraldo M, Salaffi F, Furlanut M et al. Somatomedin C (insulin-like growth factor 1) levels decrease during acute changes of stress related hormones. Relevance for fibromyalgia. J Rheumatol 1994;21:1332-4.
14. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20:469-74.
15. Crofford LJ, Pillemer SR, Kalogeras KT et al. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994;37: 1583-92.
16. Ferraccioli G, Cavalieri F, Salaffi F, Fontana S, Scita F, Nolli M et al. Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). [Editorial] J Rheumatol 1990;17:869-73.
17. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other aminoacids in primary fibromyalgia: a controlled study. J Rheumatol 1992; 19:90-4.
18. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6.
19. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986;29: 655-9.
20. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986;29:1371-7.
21. Carette S, Bell MJ, Reynolds WJ et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994;37:32-40.
22. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991;18:447-51.
23. Godfrey RG. A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch Intern Med 1996;156:1047-52.
24. Wolfe A, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994;23:255-9.
25. Norregaard J, Volksmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995;61:445-9.
26. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996;39:1852-9.
27. Da Prada M, Pieri L, Cesura AM, Kettler R. The pharmacology of moclobemide. Rev Contemp Pharmacother 1994;5:1-18.
28. Stabl M, Biziere K, Schmid-Burgk W, Amrein R. Review of comparative clinical trials: moclobemide vs tricyclic antidepressants and vs placebo in depressive states. J Neural Transm 1989;suppl.28:77-90.
29. Versiani M, Occero U, Alterwein I et al. A double-blind comparative trial of moclobemide vs imipramine and placebo in major depressive episodes. Br J Psychiatry 1989;155:72-7.
30. Priest RG, Schmid-Burgk W. Moclobemide in the treatment of depression. Rev Contemp Pharmacother 1994;5:35-43.
31. Versiani M, Nardi E, Vasconcelos-Figueira IL, Stabl M. Tolerability of moclobemide, a new reversible inhibitor of MAO-A (RIMA) in comparison with other antidepressants and placebo. Acta Psychiatrica Scand 1990;82(suppl. 360):24-8.
32. Stein MB, Hazen AL, Eldridge GD, Walker JR. SCID-Ro, Version 2.0. Structured clinical interview for DSM-III-R, revised for use in Hoffmann-LaRoche Moclobemide Anxiety Disorders Program.
33. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E. A quantitative approch to perceived health status: a validation study. J Epidemiol Community Health 1980;34:281-6.
34. EC note for guidance: Good clinical practice for trials on medicinal products in the European Community. III/3976/88-EN Final. 4.5.1990.
35. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
36. Sindrup SH, Bjerre U, Fejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther 1992;52:547-52.
37. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-44.
38. Sörensen J, Bengtsson A, Ahlner J, Henriksson KG, Ekselius L, Bengtsson M. Fibromyalgia - are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 1997;24:615-21.
39. Martin GR, Humphrey PPA. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 1994;33:261-73.
40. Hrycaj P, Stratz T, Mennet P, Müller W. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome - a preliminary study. J Rheumatol 1996;23:1418-23.
41. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32:21-6.
42. Russell IJ, Orr MD, Littman B et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37: 1593-601.
43. Wallace D. The fibromyalgia syndrome. Ann Med 1997;29:9-21.
44. Moldofsky H, Scarisbrick P, England R, Smythe HA. Musculoskeletal symptoms and non-REM sleep disturbance in patients with 'fibrositis syndrome' and healthy subjects. Psychosom Med 1975;37:341-51.
45. Reynolds WJ, Moldofsky H, Saskin P, Lue FA. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol 1991;18:452-4.
46. Jacobs JWG, Rasker JJ, van der Heijde A et al. Lack of correlation between the mean tender point score and self-reported pain in fibromyalgia. Arthritis Care Res 1996;9:105-11.
47. Urrows S, Affleck G, Tennen H, Higgins P. Unique clinical and psychological correlates of fibromyalgia tender points and joint tenderness in rheumatoid arthritis. Arthritis Rheum 1994;37:1513-20.
48. Pattrick M, Swannell A, Doherty M. Chlormethazone in primary fibromyalgia syndrome: a double blind placebo controlled study. Br J Rheumatol 1993;32:55-8.